JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product

Lynne T. Braun, Joseph J. Saseen, Carl Edward Orringer, Neil J. Stone, John R. Guyton

Research output: Contribution to journalReview article

Abstract

In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.

Original languageEnglish (US)
Pages (from-to)345-355
Number of pages11
JournalJournal of Clinical Lipidology
Volume13
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Cholesterol
Guidelines
Premature Menopause
Committee Membership
Hyperlipoproteinemia Type II
Hypertriglyceridemia
Apolipoproteins B
Physiologic Monitoring
Pre-Eclampsia
Chronic Renal Insufficiency
Population Groups
LDL Cholesterol
Coronary Vessels
Communication
Calcium
Costs and Cost Analysis
Therapeutics
oxidized low density lipoprotein

Keywords

  • Cholesterol guidelines
  • Coronary calcium scoring
  • Cost value assessment
  • Evidence-based medicine
  • Lipid clinical practice
  • Risk-enhancing factors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines : Process and product. / Braun, Lynne T.; Saseen, Joseph J.; Orringer, Carl Edward; Stone, Neil J.; Guyton, John R.

In: Journal of Clinical Lipidology, Vol. 13, No. 3, 01.05.2019, p. 345-355.

Research output: Contribution to journalReview article

Braun, Lynne T. ; Saseen, Joseph J. ; Orringer, Carl Edward ; Stone, Neil J. ; Guyton, John R. / JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines : Process and product. In: Journal of Clinical Lipidology. 2019 ; Vol. 13, No. 3. pp. 345-355.
@article{91eda95b1f1b43a2afb9d53c601c6a96,
title = "JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product",
abstract = "In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.",
keywords = "Cholesterol guidelines, Coronary calcium scoring, Cost value assessment, Evidence-based medicine, Lipid clinical practice, Risk-enhancing factors",
author = "Braun, {Lynne T.} and Saseen, {Joseph J.} and Orringer, {Carl Edward} and Stone, {Neil J.} and Guyton, {John R.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.jacl.2019.05.008",
language = "English (US)",
volume = "13",
pages = "345--355",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines

T2 - Process and product

AU - Braun, Lynne T.

AU - Saseen, Joseph J.

AU - Orringer, Carl Edward

AU - Stone, Neil J.

AU - Guyton, John R.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.

AB - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.

KW - Cholesterol guidelines

KW - Coronary calcium scoring

KW - Cost value assessment

KW - Evidence-based medicine

KW - Lipid clinical practice

KW - Risk-enhancing factors

UR - http://www.scopus.com/inward/record.url?scp=85067449315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067449315&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2019.05.008

DO - 10.1016/j.jacl.2019.05.008

M3 - Review article

C2 - 31229021

AN - SCOPUS:85067449315

VL - 13

SP - 345

EP - 355

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 3

ER -